CDC Director Resigns Over Unresolved Conflicts of Interest

Brenda Fitzgerald had drawn criticism for tobacco-related investments, among others.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

CDC signFLICKR, RAED MANSOURFollowing a report by Politico that she had purchased shares in tobacco, pharmaceutical, and health insurance companies early in her tenure as director of the Centers for Disease Control (CDC), Brenda Fitzgerald resigned from the agency today (January 31). Fitzgerald had previously been criticized by Senator Patty Murray (D-WA) for financial investments that led her to recuse herself from involvement in some aspects of CDC’s work, The Washington Post reports.

“You don’t buy tobacco stocks when you are the head of the CDC,” Richard Painter, a former chief ethics lawyer for George W. Bush, tells Politico. “It’s ridiculous; it gives a terrible appearance.”

According to a Department of Health and Human Services statement announcing the departure, “Dr. Fitzgerald owns certain complex financial interests that have imposed a broad recusal limiting her ability to complete all of her duties as the CDC Director. Due to the nature of these financial interests, Dr. Fitzgerald could not divest from them in a definitive time period.”

Before assuming the CDC post in July 2017, Fitzgerald had worked as an obstetrician-gynecologist. She had also served as a major in the Air Force and as chief of Georgia’s state health department.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Shawna Williams

    Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor's degree in biochemistry from Colorado College and a graduate certificate and science communication from the University of California, Santa Cruz.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio